A prospective study of laboratory findings in dapsone treated patients with Pemphigus vulgaris and foliaceus

被引:0
作者
Afrasiabi, Mona [1 ]
Esmaeilinejad, Shabnam [2 ]
Asgary, Vahid [3 ]
Cohan, Reza Ahangari [4 ]
Naji, Tahereh [1 ]
Seirafi, Hassan [5 ]
Bigdeli, Razieh [6 ]
Mohamadi, Sepideh [7 ]
机构
[1] Islamic Azad Univ, Pharmaceut Sci Branch, Tehran, Iran
[2] Payam E Noor Univ, East Tehran Branch, Dept Publ Biol, Tehran, Iran
[3] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran
[4] Pasteur Inst Iran, New Technol Res Grp, Dept Pilot Nanobiotechnol, Tehran, Iran
[5] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Tehran, Iran
[6] Javid Biotechnol Co, Incubator Pasteur Inst Iran, Res & Dev Lab, Tehran, Iran
[7] Ayatollah Taleghani Hosp, Cent Lab, Tehran, Iran
来源
BIOMEDICAL RESEARCH-INDIA | 2017年 / 28卷 / 03期
关键词
Pemphigus vulgaris; Pemphigus foliaceus; Dapsone; Biomedical markers; CIMETIDINE;
D O I
暂无
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Background: Pemphigus is an autoimmune disorder of skin and mucous membranes that appears in the form of blistering on skin and mucous membrane and may lead to loss of life in the absence of proper treatment. Treatment is effected by using immunosuppressant drugs such as Azathioprine cyclophosphamide and some others. Objective: Our purpose of this study was to survey about blood, hepatic and renal side effects of dapsone with the patients affected by Pemphigus. Methods: The test was carried out on 37 patients who were suffering from acute Pemphigus and had undergone some therapy with dapsone amongst which 5 patients were excluded from the research because of hepatic and hematic symptoms. The study was carried on with 31 patients with an average age of 40 +/- 17.5. They had no symptoms necessitating the stop of administration of the medicine. Results: Statistical analysis indicated no significant difference in the test results before and after the therapy and only platelet counts showed significant difference before and after the therapy (p<0.05). Conclusion: This study indicated that among all disagreements about dapsone treatment, dapsone can be applied as adjuvant therapy.
引用
收藏
页码:1066 / 1069
页数:4
相关论文
共 14 条
[1]  
BYRD SR, 1991, LEPROSY REV, V62, P171
[2]   THE USE OF CIMETIDINE AS A SELECTIVE INHIBITOR OF DAPSONE N-HYDROXYLATION IN MAN [J].
COLEMAN, MD ;
SCOTT, AK ;
BRECKENRIDGE, AM ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (05) :761-767
[3]   THE USE OF CIMETIDINE TO REDUCE DAPSONE-DEPENDENT METHEMOGLOBINEMIA IN DERMATITIS-HERPETIFORMIS PATIENTS [J].
COLEMAN, MD ;
RHODES, LE ;
SCOTT, AK ;
VERBOV, JL ;
FRIEDMANN, PS ;
BRECKENRIDGE, AM ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (03) :244-249
[4]   DAPSONE - MODES OF ACTION, TOXICITY AND POSSIBLE STRATEGIES FOR INCREASING PATIENT TOLERANCE [J].
COLEMAN, MD .
BRITISH JOURNAL OF DERMATOLOGY, 1993, 129 (05) :507-513
[5]   Efficacy of dapsone in the treatment of pemphigus and pemphigoid: Analysis of current data [J].
Grcan H.M. ;
Ahmed A.R. .
American Journal of Clinical Dermatology, 2009, 10 (6) :383-396
[6]   Guidelines for the management of pemphigus vulgaris [J].
Harman, KE ;
Albert, S ;
Black, MM .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (05) :926-937
[7]   Current therapy of the pemphigus group [J].
Kasperkiewicz, Michael ;
Schmidt, Enno ;
Zillikens, Detlef .
CLINICS IN DERMATOLOGY, 2012, 30 (01) :84-94
[8]   Successful Treatment of Pemphigus Vulgaris With the Extensive Mucocutaneous Lesions in an Elderly Patient [J].
Masjedi, Mohsen ;
Asilian, Ali ;
Shahmoradi, Zabihollah ;
Dehnavi, Parvin Rajabi ;
Naeini, Bahareh Abtahi .
IRANIAN RED CRESCENT MEDICAL JOURNAL, 2014, 16 (06)
[9]   Molecular Diagnosis in Autoimmune Skin Blistering Conditions [J].
Otten, J. V. ;
Hashimoto, T. ;
Hertl, M. ;
Payne, A. S. ;
Sitaru, C. .
CURRENT MOLECULAR MEDICINE, 2014, 14 (01) :69-95
[10]  
RHODES LE, 1995, BRIT J DERMATOL, V132, P257